Compare GSK plc (GSK) vs ProShares UltraPro S&P500 (UPRO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs ProShares UltraPro S&P500 — how do they compare? GSK plc trades at $46.5 (market cap $91.88B), while ProShares UltraPro S&P500 trades at $155.73 (market cap $5.55B). The key difference: GSK plc is far larger — about 16.6× ProShares UltraPro S&P500's market cap, and GSK plc pays a 3.9% dividend while ProShares UltraPro S&P500 pays none. Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and ProShares UltraPro S&P500 for 29 Days on average.
| GSK | UPRO | |
|---|---|---|
Market Cap | $91.88B | $5.55B |
Volume | 7,730,529 | 2,078,694 |
Sector | Health | Leveraged / Inverse |
52-Week High | $61.18 | $157.66 |
52-Week Low | $43.24 | $89.29 |
Typical Hold Time | 93 Days | 29 Days |
Enterprise Value | $111.88B | — |
Dividend Yield | 3.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $46.54, down 1.02% on the day, with a bearish technical signal from moving averages but oversold RSI readings. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $1.36 exceeding the $1.27 estimate. Fundamentals show robust profitability with a 72.73% gross margin and 14.52% net margin, while valuation metrics like a P/E of 14.89 appear reasonable. Recent news highlights pipeline advancements, including a $750 million cancer therapy deal and strategic focus on oncology and cost savings.
The outlook is mixed; analyst consensus leans Hold (55.18%) with a minority Buy rating (31.03%), reflecting caution amid an approaching HIV patent cliff. Near-term support is at $45, with resistance at $47. Revenue growth to $33.2B in 2026 and a dividend of $0.45 per share offer stability, but execution risks and competitive pressures remain key watchpoints for investors.
UPRO trades at $153.19, down 1.3% on the day, with technical indicators showing a bullish moving average trend but neutral oscillators. The stock faces resistance at $155 and support at $151. Recent news highlights S&P 500 valuation concerns and expected profit growth deceleration from 35% in 2026 to 15% in 2027, creating mixed sentiment around the broader market environment.
The outlook for UPRO is influenced by broader market dynamics, with Wall Street expecting continued S&P 500 gains but facing headwinds from concentration risks and economic uncertainty. Key opportunities include potential year-end rallies, while risks involve market volatility and earnings growth slowdowns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About ProShares UltraPro S&P500
UPRO is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to three times (3x) the daily performance of the S&P 500 Index. It is a tactical, high-conviction instrument designed for short-term traders to amplify bullish market moves, utilizing a daily reset mechanism that creates significant compounding effects and volatility risks over time.
Read more on UPRO →
